Daiichi Sankyo Company Past Earnings Performance
Past criteria checks 5/6
Daiichi Sankyo Company has been growing earnings at an average annual rate of 15.9%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 13% per year. Daiichi Sankyo Company's return on equity is 15.4%, and it has net margins of 14.2%.
Key information
15.9%
Earnings growth rate
16.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 13.0% |
| Return on equity | 15.4% |
| Net Margin | 14.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Daiichi Sankyo Company makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,758,071 | 250,400 | 696,740 | 392,404 |
| 30 Jun 24 | 1,687,028 | 229,101 | 675,532 | 388,731 |
| 31 Mar 24 | 1,601,688 | 200,731 | 636,997 | 365,169 |
| 31 Dec 23 | 1,503,471 | 186,052 | 578,348 | 358,217 |
| 30 Sep 23 | 1,397,025 | 147,885 | 538,976 | 357,008 |
| 30 Jun 23 | 1,348,996 | 147,350 | 511,428 | 343,791 |
| 31 Mar 23 | 1,278,478 | 109,188 | 471,221 | 341,570 |
| 31 Dec 22 | 1,182,201 | 59,354 | 435,551 | 331,522 |
| 30 Sep 22 | 1,122,724 | 62,816 | 404,552 | 301,836 |
| 30 Jun 22 | 1,061,140 | 50,603 | 375,565 | 281,129 |
| 31 Mar 22 | 1,044,892 | 66,972 | 358,309 | 260,228 |
| 31 Dec 21 | 1,034,692 | 94,470 | 357,377 | 232,834 |
| 30 Sep 21 | 1,012,313 | 86,756 | 348,080 | 231,885 |
| 30 Jun 21 | 989,638 | 79,321 | 340,406 | 232,560 |
| 31 Mar 21 | 962,516 | 75,958 | 333,079 | 227,353 |
| 31 Dec 20 | 963,552 | 70,599 | 323,363 | 224,168 |
| 30 Sep 20 | 982,388 | 116,315 | 320,481 | 216,129 |
| 30 Jun 20 | 969,501 | 117,584 | 310,949 | 205,104 |
| 31 Mar 20 | 981,793 | 129,074 | 302,320 | 197,465 |
| 31 Dec 19 | 983,669 | 148,891 | 287,414 | 198,066 |
| 30 Sep 19 | 962,440 | 113,821 | 279,588 | 195,904 |
| 30 Jun 19 | 953,219 | 112,805 | 275,245 | 199,435 |
| 31 Mar 19 | 929,717 | 93,409 | 277,695 | 203,711 |
| 31 Dec 18 | 922,228 | 66,479 | 283,615 | 203,000 |
| 30 Sep 18 | 937,648 | 70,018 | 290,411 | 206,117 |
| 30 Jun 18 | 946,829 | 55,081 | 296,677 | 233,531 |
| 31 Mar 18 | 960,195 | 60,282 | 301,845 | 236,046 |
| 31 Dec 17 | 961,766 | 37,887 | 298,758 | 246,479 |
| 30 Sep 17 | 966,509 | 38,758 | 300,781 | 242,153 |
| 30 Jun 17 | 953,255 | 52,017 | 303,760 | 215,721 |
| 31 Mar 17 | 955,124 | 53,466 | 302,475 | 214,347 |
| 31 Dec 16 | 962,296 | 59,736 | 316,918 | 214,027 |
| 30 Sep 16 | 965,681 | 60,572 | 325,970 | 216,074 |
| 30 Jun 16 | 989,001 | 77,951 | 326,613 | 211,564 |
| 31 Mar 16 | 986,446 | 82,282 | 328,755 | 208,656 |
| 31 Dec 15 | 839,759 | 55,256 | 269,399 | 186,615 |
| 30 Sep 15 | 872,744 | 67,132 | 284,021 | 190,206 |
| 30 Jun 15 | 903,340 | 61,708 | 306,873 | 191,180 |
| 31 Mar 15 | 919,372 | 46,762 | 331,195 | 190,666 |
| 31 Dec 14 | 1,149,342 | 88,276 | 266,861 | 333,388 |
| 30 Sep 14 | 1,127,233 | 80,437 | 405,500 | 185,139 |
| 30 Jun 14 | 1,120,177 | 69,910 | 361,139 | 234,391 |
| 31 Mar 14 | 1,118,241 | 60,943 | 413,187 | 191,212 |
| 31 Dec 13 | 1,059,287 | 90,021 | 419,188 | 183,047 |
Quality Earnings: D4S0 has high quality earnings.
Growing Profit Margin: D4S0's current net profit margins (14.2%) are higher than last year (10.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: D4S0's earnings have grown by 15.9% per year over the past 5 years.
Accelerating Growth: D4S0's earnings growth over the past year (69.3%) exceeds its 5-year average (15.9% per year).
Earnings vs Industry: D4S0 earnings growth over the past year (69.3%) exceeded the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: D4S0's Return on Equity (15.4%) is considered low.